Azithromycin Plus Hydroxychloroquine for COVID-19 Infection
Status:
Withdrawn
Trial end date:
2021-08-26
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, Phase 3, multi-center trial of the clinical and
microbiologic response of patients with a respiratory tract infection (RTI) due to
coronavirus treated with a combination of azithromycin and hydroxychloroquine.
Approximately 200 patients with symptoms of an RTI who test positive for SARS-CoV-2 by
polymerase chain reaction (PCR) will receive a combination of azithromycin 500 mg and
hydroxychloroquine 600 mg or matching placebos for six consecutive days. There will be two
treatment regimens into which patients are randomized so that all patients will receive some
active therapy.